Canada markets close in 5 hours 54 minutes

FluroTech Ltd. (TEST.V)

TSXV - TSXV Real Time Price. Currency in CAD
Add to watchlist
0.1850+0.0050 (+2.78%)
As of 10:05AM EDT. Market open.
Full screen
Previous Close0.1800
Open0.1850
Bid0.1800 x 0
Ask0.1850 x 0
Day's Range0.1850 - 0.1850
52 Week Range0.0850 - 0.8500
Volume4,170
Avg. Volume211,496
Market Cap22.313M
Beta (5Y Monthly)-1.67
PE Ratio (TTM)N/A
EPS (TTM)-0.0460
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • FluroTest Announces Pre-Emergency Use Authorization Filing with FDA; Provides Executive Update on Program Progress
    GlobeNewswire

    FluroTest Announces Pre-Emergency Use Authorization Filing with FDA; Provides Executive Update on Program Progress

    CALGARY, Alberta, July 12, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, today announced it has filed its Pre-Emergency Use Authorization (Pre-EUA) Request with the U.S. Food and Drug Administration (FDA). The Pre-EUA submission is the Company’s latest step taken as it

  • FluroTest Diagnostic Systems Featured in Grand View Research Report Exploring Growth of COVID-19 Saliva Screening Test Potential Market
    GlobeNewswire

    FluroTest Diagnostic Systems Featured in Grand View Research Report Exploring Growth of COVID-19 Saliva Screening Test Potential Market

    CALGARY, Alberta, June 17, 2021 (GLOBE NEWSWIRE) -- FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to be recognized in Grand View Research’s June 2021 report: COVID-19 Saliva Screening Test Potential Market. According to the report, the global COVID-19 saliva screening test potentia

  • Former US Assistant Health Secretary Dr. Joxel Garcia Joins FluroTest as Chief Medical Officer and Executive Team Member
    CNW Group

    Former US Assistant Health Secretary Dr. Joxel Garcia Joins FluroTest as Chief Medical Officer and Executive Team Member

    FluroTech LTD. (TSXV: TEST) (OTCQB: FLURF) and wholly owned subsidiary FluroTest Diagnostic Systems ("FluroTest" or The Company), a diagnostics technology leader in high output rapid antigen testing for the detection of SARS-CoV-2 and other pathogens, are pleased to announce the appointment of former U.S. Public Health Service and Four-Star Admiral Joxel Garcia, M.D. to Chief Medical Officer (CMO). Dr. Garcia will be responsible for expanding FluroTest's domestic and international reach while dr